Page 11 - Thomask Equels News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomask Equels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomask Equels Today - Breaking & Trending Today

AIM ImmunoTech Inc.: AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center

Published: January 17, 2023

Research collaboration will evaluate the potential of AIM's Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi (durvalumab) for the treatment of pancreatic cancerOCALA, Fla., Jan. 17, 2023

Source: finanznachrichten.de

Related Topics:

AIM ImmunoTech to Present at the 'Virtual Investor 2023

Published: January 5, 2023

Live video webcast on Wednesday, January 18th at 11:00 AM ET...

Source: globenewswire.com

Related Topics:

United States Thomask Equels Companies To Watch Event On Immunotech Inc Early Access Program Netherlands At Erasmus Medical Center Executive Officer Thomas Virtual Investor Watch Event Erasmus Medical Center Nyse Aim Aim Immunotech Inc

AIM ImmunoTech Inc.: AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen (Rintatolimod) in Healthy Subjects

Published: December 8, 2022

Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a prophylactic or early treatment against respiratory viral

Source: finanznachrichten.de

Related Topics:

United Kingdom Davidr Strayer Thomask Equels Company On Twitter Immunotech Inc British Society For Immunology Congress Early Access Program Netherlands At Erasmus Medical Center British Society Immunology Congress Executive Officer Thomas Medical Officer Western Equine Encephalitis Virus Vaccinia Virus Erasmus Medical Center Private Securities Litigation Reform Act

AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen (Rintatolimod) in Healthy Subjects

Published: December 8, 2022

08.12.2022 - Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a prophylactic or early treatment against respiratory viral infections Data presented in poster ... Seite 1

Source: wallstreet-online.de

Related Topics:

United States United Kingdom Lisanne Ca Smidt Thomask Equels Centre For Human Drug Research Immunotech Inc British Society For Immunology Congress Human Drug Research British Society Immunology Congress Executive Officer Thomas

AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease

Published: November 3, 2022

AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease - read this article along with other careers information, tips and advice on BioSpace

Source: biospace.com

Related Topics:

United States Jenene Thomas Thomask Equels Company On Twitter Immunotech Inc Drug Administration Early Access Program Netherlands At Erasmus Medical Center Orphan Drug Designation Chief Executive Officer Western Equine Encephalitis Virus Vaccinia Virus Drug Designation Erasmus Medical Center Ebola Virus Disease Disease Control Developing Products Rare Diseases Im Immunotech Receives Orphan Drug Designation For Ampligen Rintatolimod The Treatment Of Ebola Virus Disease

Page 12 Page 13 Page 14 Page 15